Access Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of novel therapeutics for the treatment of cancer and supportive care of cancer patients. It offers MuGard for the management of oral mucositis. The company s product candidates include ProLindac, a nanopolymer Diamino Cyclohexane platinum prodrug that is in Phase II clinical trial for the treatment of cancer; CobOral, a preclinical nanopolymer oral drug delivery technology based on the natural vitamin B12 oral uptake mechanism; and CobaCyte, a preclinical mediated targeted delivery technology that uses nanopolymer constructs to deliver anti-cancer drug to tumors while protecting normal tissues. It is also developing oral insulin for diabetes. Access Pharmaceuticals, Inc. was founded in 1988 and is based in Dallas, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for ACCP